DALE WALLINGTON: Open Payments
NPI 1609838689 · WEST HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,675 in 187 payments from 20 companies in 2025. Trend: 2023 $2,822 · 2024 $3,342 · 2025 $3,675
Food & beverage: $3,675
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $618 |
| Teva Pharmaceuticals USA, Inc. | 25 | $501 |
| E.R. Squibb & Sons, L.L.C. | 20 | $382 |
| Neurocrine BioSciences, Inc. | 17 | $310 |
| Janssen Pharmaceuticals, Inc | 13 | $262 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $251 |
| Otsuka America Pharmaceutical, Inc. | 12 | $244 |
| Lundbeck LLC | 17 | $228 |
| Vanda Pharmaceuticals Inc. | 11 | $202 |
| Alkermes, Inc. | 5 | $121 |
Products named: VRAYLAR, REXULTI, COBENFY, UZEDY, INGREZZA, CAPLYTA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across CT — which companies pay providers there.
